Vascular Specialist International : eISSN 2288-7989 / pISSN 2288-7970

Table. 1.

Table. 1.

Cases and/or series of PAUs stratified according to the year of publication, number of patients, age, sex, risk factors, and treatment characteristics

Study (reference) Number of patients Mean age (y) Sex (male/female) Risk Treatment
Lagaay [21] 3 58 3/0 HTN-CAD ABI (2)-tube (1)
Cornud et al. [22] 1 53 1/0 CAD Tube
Barbier et al. [23] 1 73 0/1 NA ABI
Aschraft et al. [24] 1 60 0/1 HTN-PAD Tube
Nora and Hollier [25] 1 56 1/0 HTN Surgical interposition graft
Barba et al. [26] 1 37 1/0 NA Surgical interposition graft
Rothwell and Lane [27] 1 72 1/0 HTN Tube
Harris et al. [13] 10 74 10/0 HTN-CKD-CAD Medical (3), surgical interposition graft (7)
Origuchi et al. [28] 4 59 3/1 HTN (1) ABI (3)-tube (1)
Goldstein et al. [29] 1 67 1/0 HTN-CAD Dacron aorto-iliac graft
Moriyama et al. [30] 1 74 1/0 HTN Woven Dacron aorto-iliac graft
Taylor nd Kalman [31] 4 73 4/0 HTN-CAD-PAD Tube Dacron (2)-Dacron patch (2)
Hayashi et al. [32] 1 73 1/0 NA Medical
Quint et al. [33] 1 NA Medical
Toda et al. [34] 2 70 2/0 HTN-CAD-PAD Surgical interposition graft
Farooq et al. [35] 2 68 2/0 HTN (2)-PAD ABI (1)-tube (1)
Ganaha et al. [12] 31 71 15/16 HTN Interposition stent graft
Tsuji et al. [17] 4 79.5 4/0 HTN (4)-CAD (2) EVAR (4)
Vasquez et al. [36] 1 81 1/0 HTN (1) Stent graft
Saiki et al. [37] 1 81 0/1 HTN (1) Resection graft (AFB)
Feld et al. [38] 1 68 1/0 CKD EVAR (1)
Minor et al. [39] 2 55 2/0 HTN-CAD-PAD ABI (2)
Ventura et al. [40] 1 68 0/1 HTN (1) ABI
Takagi et al. [41] 1 64 1/0 NA Surgical interposition graft
Batt et al. [18] 8 70 7/1 HTN (4)-CAD (3)-PAD (6) Surgical interposition graft (5) (tube 3-Dacron aorto-iliac graft 2)- EVAR (3)
Chernenkov et al. [42] 1 80 1/0 HTN Tube
Tanigushi et al. [43] 1 82 0/1 CAD Hemashield tube, left aortorenal bypass
Sensi et al. [44] 11 76.7 10/1 HTN (9)-CKD (1)-CAD (6) ABI (4)-tube (1)- EVAR (6)
Eggebrecht et al. [45] 22 69.1 16/6 HTN (2)-CKD (9)-CAD (12) EVAR (22)
Thalheimer et al. [46] 1 57 1/0 HTN-CAD-PAD Tube (1)
Dalainas et al. [47] 2 68.6 2/0 HTN (2)-CKD (2)-CAD (5) EVAR (2)
Piffaretti et al. [48] 13 73 12/1 HTN (13)-CKD (2)-CAD (2)-PAD (6) EVAR (13)
Fyntanidou et al. [49] 4 67 4/0 HTN (4)-CKD (1)-CAD (1) EVAR (4)
Lindblad et al. [50] 19 72 16/3 NA EVAR (19)
Afifi et al. [51] 1 76 0/1 HTN-CAD-PAD EVAR (1)
Hyhlik-Dürr et al. [52] 20 72 20/0 HTN (19)-CKD (4)-CAD (8) EVAR (20)
Kutsukata et al. [53] 1 64 0/1 HTN Dacron aorto-iliac graft (1)
Ferro et al. [54] 1 64 0/1 HTN-CAD EVAR (1)
Kainuma et al. [55] 1 67 1/0 HTN EVAR (1)
Nathan et al. [56] 20 NA EVAR (10)-open repair (10)
Sadeghi-Azandaryani et al. [57] 1 76 1/0 HTN-CAD EVAR (1)
Kazan et al. [58] 3 71 2/1 HTN (1)-CAD EVAR (3)
Palombo et al. [59] 3 67 3/0 HTN (3)-CKD (2)-CAD (4)-PAD (2) EVAR (3)
Papazoglou et al. [60] 1 69 1/0 HTN EVAR
Georgiadis et al. [61] 19 70 18/1 HTN (18)-CKD (8)-CAD (11)-PAD (9) EVAR (19)
Total 230 49/164 (29.9%)a 115/164 (70.1%)b

PAUs, penetrating atherosclerotic ulcers; HTN, hypertension; CAD, coronary artery disease; ABI, aortoiliac graft; NA, not available; PAD, peripheral arterial disease; CKD, chronic kidney disease; EVAR, endovascular aneurysm repair; AFB, axillary bifemoral bypass; IMH, intramural hematoma; SA, saccular aneurysm.

Surgical treatment,
endovascular repair.
Vasc Specialist Int 2019;35:152-9 https://doi.org/10.5758/vsi.2019.35.3.152
© 2019 The Korean Society for Vascular Surgery